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Aim: In patients with isocitrate dehydrogenase (IDH) mutated anaplastic glioma determine the dosimetric benefits
of delivering radiation therapy using a PET guided integrated boost IMRT technique (ib-IMRT) compared with
standard IMRT (s-IMRT) in reducing dose to normal brain.
Methods: Ten patients with anaplastic glioma, identified as a favourable molecular subgroup through presence of
IDH mutation, and managed with radiation therapy using an ib-IMRT were enrolled into a dosimetric study comparing
two RT techniques: s-IMRT to 59.4Gy or ib-IMRT with 59.4/54Gy regions. Gross Tumour volume (GTV) and Clinical Target
Volumes (CTV) were determined by MRI, 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET imaging.
A standard risk Planning Target Volume (PTVsr) receiving 59.4Gy (PTV59.4) in the s-IMRT technique was determined
by MRI T2Flair and FET PET. For the ib-IMRT technique this PTVsr volume was treated to 54Gy, and the high-risk PTV
(PTVhr) receiving 59.4Gy was determined as a higher risk region by FDG PET and MRI gadolinium enhancement.
Standard dosimetric criteria and normal tissue constraints based on recent clinical trials were used in target delineation
and planning. Normal Brain was defined as Brain minus CTV. Endpoints for dosimetric evaluation related to mean Brain
dose (mBrainDose), brain volume receiving 40Gy (Brainv40) and 20Gy (Brainv20). The variation between the dosimetric
endpoints for both techniques was examined using Wilcoxon analysis.
Results: The 10 patients had tumours located in temporal (1), parietal (3), occipital (2) and bifrontal (4) regions. In
ib-IMRT technique the median volume of PTVhr was 25.5 cm3 compared with PTVsr of 300.0 cm3. For dose to PTVhr
the two treatments were equivalent (p = 0.33), and although the ibIMRT had a prescribed 10% dose reduction from
59.4Gy to 54Gy the median reduction was only 5.9%. The ib-IMRT dosimetry was significantly improved in normal
brain endpoints specifically mBrainDose (p = 0.007), Brainv40 (p = 0.005) and Brainv20 (p = 0.001), with a median
reduction of 9.3%, 19.0 and 10.8% respectively. After a median follow-up of 38 months two patients have progressed,
with no isolated relapse in the dose reduction region.
Conclusion: An approach using ib-IMRT for anaplastic glioma produces significant dosimetric advantages in relation to
normal brain dose compared with s-IMRT plan. This is achieved without a significant reduction to the target
volume dose despite the reduction in prescribed dose. This technique has advantages to minimise potential
late neurocognitive effects from high dose radiation in patients with favorable subtype anaplastic glioma with
predicted median survival beyond ten years.
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Anaplastic oligodendroglial tumours are a favourable
subsite of high grade glioma that have recently been
shown to be associated with median survival beyond
10–15 years with management by combined modality
therapy with limited surgery, radiation therapy and
chemotherapy [1, 2]. In recent years these and other
patients whose tumours are harbouring an isocitrate
dehydrogenase (IDH) mutation are being classified into
a more favourable subgroups of patients with prolonged
survival [3–5]. Patients are often diagnosed at a youn-
ger age and present with symptoms such as limited
seizure activity without major morbidity or affect on
performance status. The more durable survival in this
high functioning younger population places a greater
emphasis on optimizing therapy with a balance between
tumour control and minimization of late morbidity.
Although favourable prognosis with variable growth
rate, the tumour is often quite extensive at initial pres-
entation with MRI demonstrating widespread T2 Flair
change surrounding the initial T1 dense or enhancing
mass [6, 7]. Radiation therapy is the key component of
management but high dose therapy and large volume
standard treatment has been associated with late neu-
rocognitive effects that will reach clinical significance
in patients with durable survival [8, 9].
Technological improvements in diagnostic imaging,
nuclear medicine and radiation therapy treatment can
potentially deliver a more targeted dose of radiation to
the tumour and spare normal brain [10]. Similarly in
favourable anaplastic glioma (AG) there may be a less
aggressive region of the tumour that may be managed
with lower radiation dose as utilized in primary low
grade glioma.
This study aims to evaluate the dosimetric benefits of
a novel radiation approach for favourable AG utilizing
improved targeting of radiation therapy (intensity modu-
lated radiation therapy) to areas within the tumour at
different dose levels (integrated boost) defined by MRI
and nuclear medicine techniques (dose painting).
Methods
Consecutive adult patients diagnosed with AG and
referred to The Department of Radiation Oncology at
the Northern Sydney Cancer Centre were entered into
a prospective database, approved by Institutional Ethics
Review Board. 10 patients with favourable molecular
subgroup as defined by presence of IDH mutation were
included in this dosimetric study. These patients were
formally managed with definitive radiation therapy
under the departmental IMRT Integrated Boost Protocol
(ib-IMRT) adapting dosimetric criteria and constraints
specified as per the standard EORTC CATNON Proto-
col [11]. For these 10 patients an additional plan wasproduced using a standard IMRT (s-IMRT) plan with-
out integrated boost; and these plans were then utilised
for formal comparison.
Patient selection
Eligible patients for the ib-IMRT Protocol were newly
diagnosed or RT naive relapsed patients diagnosed with
an anaplastic glioma that had favourable prognosis as
defined by molecular features of IDH1 mutation or
1p19q co-deletion.
Pretreatment preparation
Patients required a gadolinium enhanced 3T MRI in the
six weeks prior to commencement of radiation therapy.
Axial T1, T2Flair and T1gad sequences were utilized for
RT Planning.
Nuclear medicine imaging with combined FET and FDG
PET were performed. The FET studies were acquired on a
Siemens Biograph mCT PET/CT scanner with extended
axial FoV and time of flight (ToF) imaging capability, with
20-min dynamic and 10-min static acquisitions following
a 3 min FET infusion period. The standard injected dose
of FET was 150 MBq.
Reconstruction parameters included 3D OSEM with
two iterations and 21 subsets with PSF recovery and
ToF. Scatter correction was model-based and attenu-
ation correction was CT-based. Post-reconstruction
Gaussian filtering was performed with filter size of
5 mm. The FDG PET involved both immediate and
4 h delayed sequences.
As based on the European guidelines, the FET-PET was
reported as pathological if the ratio of uptake was 1.6
times the background uptake of healthy brain tissue [12].
Radiation therapy planning
The patients had CT simulation with immobilization by
an individual Kevlar thermoplastic mask system. MRI
and PET scans were fused with the non-contrast CT
scan and entered into the Varian Eclipse Planning system.
Any historical MRI imaging, especially for patients
with progressive disease after prior surveillance was also
imported for assistance with target volume determination.
The quality of fusion was confirmed with comparison of
manually generated structures (surgical cavity, ventricular
system and pons) using the non-contrast planning CT as
the reference. A single clinician and dosimetrist were used
for the planning process.
Target volume segmentation for ib-IMRT
The gross tumour volume was developed from a com-
bination of volumes generated from each of the
imported MRI sequences; specifically Gross Tumour
Volume (GTV) T1, GTVT2F, GTVT1gd, GTVFET and
GTVFDG. The GTVT2F included all of the T2Flair
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ventricular changes.
The GTVFET was generated manually based on up-
take normalized to the blood flow uptake in the sagittal
sinus. The GTVT2F was correlated with the GTVFET
to clarify areas of subtle T2Flair or alternatively subtle
FET uptake.
Subsequently high and standard risk GTVs were de-
veloped for the integrated boost and named GTVhr
and GTVsr as corresponding to the dose levels 59.4Gy
and 54Gy. The higher risk region GTVhr comprised
the GTVT1gd (any pre or postop enhancing tumour)
and GTVFDG. The standard risk region GTVsr com-
prised the GTVhr as well as GTVT2F and GTVFET.
The GTVsr was then reviewed with GTVT1 and the
surgical cavity on planning CT to confirm coverage;
though the surgical cavity was excluded if there was a
large CSF collection contiguous with the dura.
If the T2Flair change was noted to have FET uptake,
then it was managed as non-enhancing tumour and
included in the GTVsr, receiving a prescribed dose of
54Gy. If no FET uptake was evident (and no FDG
uptake or increased T1density) then the T2 Flair was
presumed to be edema or gliosis and was not routinely
incorporated into the GTVsr. As the MRI was the key
diagnostic modality to define target volumes then if
there was FET uptake, but at a lower volume, within
the T2 Flair then the whole of the MRI abnormality
was included within the GTVsr. However if there was
FET uptake outside of the T2Flair, the protocol would
include that region in the GTVsr.
A high-risk clinical target volume (CTVhr) was cre-
ated from GTVhr and expansion of 2 mm. The standard
risk clinical target volume (CTVsr) was created from
GTVsr and expansion of 10 mm. Both were restricted at
anatomical boundaries.
Final planning target volumes (PTVhr and PTVsr) were
created from corresponding CTV with an additional ex-
pansion of 0 mm and 3 mm respectively.
There is specifically no expansion to the PTVhr as it is
understood that the CTVhr is always covered by the
CTVsr and this latter volume is expanded by 3 mm.
Thus any setup error within the 3 mm measured depart-
mental error for IGRT will mean the PTVhr will be in
the region receiving 54–59.4Gy.
Normal tissue segmentation
Multiple normal tissue structures were generated based
on the T1 MRI but reviewed with the planning CT and
modified if variation. IMRT Planning priorities were
weighted to dose tolerance placed on optic chiasm and
nerves (maximum 5500 cGy) and brainstem (5500 cGy
with <1 cm3 allowed at 6000 cGy). For the PTV struc-
tures, 100% of dose had to be delivered to 95% of thetarget volume. Additionally hippocampal structures were
delineated to encompass the surrounding medial tem-
poral lobe. The dose to the contralateral hippocampus
was minimized to a mean dose range between of 15Gy-
20Gy. The ipsilateral hippocampus was restricted to
this dose level if uninvolved by PTVsr; and optimally a
mean dose of 40Gy if partially involved.
ib-IMRT Plan generation
The dose prescription for the ib-IMRT plan was 59.4Gy
and 54Gy in 33 fractions delivered to PTVhr and PTVsr
over six and a half weeks. Coverage of 95% of the specific
PTV by 100% of the dose was the dosimetry target.
An integrated boost IMRT plan was created with in-
verse planning limited by a maximum of 6 fields and
dose constraints with highest priority on PTVhr, optic
chiasm and brainstem. At sites where PTVhr involved
a dose limiting structure, a separate high priority PTV
was created for the overlap region and optimisations
performed to control the dose at that region. Fluence
painting was undertaken on each field to remove areas
of high dose gradient. This plan was used for treatment
delivery.
Radiation therapy delivery
Treatment was delivered with IMRT using 6MV photons
on a Varian Trilogy or TrueBeam STx Linear Accelerator.
Daily IGRT was performed with the on-board imager
(OBI) verifying position based on middle cranial fossa
and orbital bone landmarks, and weekly Cone Beam
CT to exclude any significant shift of intracranial con-
tents arising from oedema, intercurrent haemorrhage
or tumour reduction.
Systemic therapy management
Patients were offered adjuvant temozolomide (TMZ) for
six months following the completion of RT. No concur-
rent chemotherapy was used with RT.
Study comparison plans
For the clinical study comparison plans were produced
for s-IMRT using an inverse planned IMRT technique
based on the generated PTVsr without a dose reduc-
tion. For these plans the PTVsr was assigned a dose of
59.4Gy in 33 fractions so that all known tumour would
be covered by the dose used in the EORTC CATNON
Protocol [11].
Dosimetric endpoints
The primary dosimetric endpoint for the study is the
mean Brain dose (defined as Whole Brain minus PTVsr).
Secondary Brain Dose parameters include percentage
volume of brain receiving 40Gy (BrainV40) and volume
of Brain receiving 20Gy (BrainV20).
Back et al. Radiation Oncology  (2017) 12:46 Page 4 of 8Other dosimetric secondary endpoints relate to dose
received by the high risk region (GTVhr) and contralat-
eral hippocampus for both sets of plans.
Clinical endpoint
All patients were managed with the ib-IMRT plan. Any
treatment failure within the PTVhr or PTVsr was re-
corded, especially in regards to isolated relapse within
the region of dose reduction to 54Gy (PTVsr).
Statistical considerations
All patients had clinical and dosimetric data entered on
an Excel database at Northern Sydney Cancer Centre
and updated for outcome events.
The variation in specific dosimetric endpoints between
the ib-IMRT and s-IMRT dosimetric endpoints was
examined using Wilcoxon analysis. Significance was
determined at the p = 0.05 level.
Results
The ten patients all received the prescribed radiation
dose with the ib-IMRT plan without any interruption
or dose modification.
The individual patient clinical and tumour characteris-
tics are detailed in Table 1. The tumours were distrib-
uted in the brain with locations in frontal (4), parietal
(3), temporal (1), occipital (2) lobes. There was evidence
of gad enhancement on MRI in 4 patients, and FDG
uptake in 7 patients. There was evidence of FET uptake
in all ten patients that was confirmed as correlating






Tumour Volume High Risk (PTVhr)
Tumour Volume Standard Risk (PTVsr)
Tumour Volume Ratio of High to Low Risk (PTVhr/PTVsr)The diffuse extent of the tumours was evident with
the volume of PTVsr which ranged from 119 cm3 to
618 cm3 with a median of 300 cm3.
Radiation planning
All generated plans achieved the minimum dosimetric
criteria for PTVsr coverage and normal tissue tolerances
in brainstem, optic chiasm and contralateral hippocam-
pus. The doses received by the high-risk tumour region
(PTVhr) were equivalent in the two planning techniques
(p = 0.33). As expected the dose reduction to the PTVsr
caused a significant reduction of dose in the integrated
boost technique (p < 0.001); however the 10% prescribed
dose reduction resulted in only a median 5.9% reduction
to the mean dose received by this region.
Dosimetric endpoints
The dosimetric brain endpoints were significantly im-
proved for all normal brain dose categories with the
ib-IMRT plans compared with the s-IMRT plans. The
results are summarized in Tables 2 and 3.
The reduction in mean brain dose for each of the pa-
tients is shown in Fig. 1, with a median reduction of 9.3%
(range 1.0 to 17.8%). The impact of the integrated boost
planning technique was demonstrated at the BrainV40
levels with the reduction of the volume of brain receiving
40Gy being significantly decreased by a median level of
19.0%, and with reductions up to 40.2% (Fig. 2). The lower
dose to the normal brain, as demonstrated by the
BrainV20 levels, paralleled the reduction of the higher
dose levels with a median reduction of 10.8% (range 1.0 to
25.8%). Similarly the contralateral brain hippocampalSubgroup Number
<40 year 2
>40 year 8











Median Range 25.5 cm3 (7.0–142.1 cm3)
Median Range 300.0 cm3 (119.2–618.1 cm3)
Median Range 11.5% (3.2–46.4%)
Table 2 Dosimetric endpoints for ibIMRT and sIMRT Plans
Endpoint ibIMRT (median and range) sIMRT (median and range) P value
PTVhr Dose (Median) 59.9Gy (58.0–60.4Gy) 59.8Gy (58.1–61.6Gy) p = 0.33
PTVsr Dose (Median) 56.0Gy (54.1–57.0Gy) 59.8Gy (58.1–61.6Gy) P < 0.001
V40 (volume of brain receiving 40Gy) 14.9% (11.8–30.4%) 18.3% (14.5–29.2%) p = 0.005
V20 (volume of brain receiving 20Gy) 45.8% (29.2–71.1%) 52.6% (35.2–68.4%) p = 0.001
Mean Dose to Brain 22.3Gy (16.3–29.9) 24.5Gy (19.3–30.9) p = 0.007
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dose with the integrated boost technique that parallels the
V20 Brain dosimetric improvements (Table 3).
Only one integrated boost plan had no impact on dosi-
metric endpoints of normal brain dose (Patient 7), and
that was the patient with the largest PTVsr and highest
normal brain doses (Fig. 3).
Specifically when averaged across the study cohort, a
prescribed reduction of dose by 5.4Gy or 10% to the low
risk region (PTVst) in the ib-IMRT plan produced a pro-
portional reduction of only 5.9% to the actual dose in
that region. However this dose reduction planning tech-
nique resulted in a much higher proportional reduction
of dose to normal brain by 9.3% (for mean brain dose)
and a reduction in the volume of brain being treated to
40Gy by 19.0%.
Clinical endpoint
At a median follow-up of 38 months in this patient co-
hort, two patients have had tumour progression. One
was distant failure outside of both PTVsr; and the other
had progression within both PTVhr and PTVsr.
Discussion
This dosimetric study confirms the benefits of utilizing
an integrated boost approach to IMRT as an attempt to
minimise the amount of radiation therapy delivered to
normal brain tissue in patients with anaplastic glioma.
The volume of normal brain receiving doses above 40Gy
was reduced by a median of 19%, with significant reduc-
tions to the mean brain dose with this technique com-
pared to standard IMRT. These dosimetric improvements
have the potential to minimise the risk of late neurocogni-
tive effects from RT by impacting on the predictive factors
of radiation dose, dose per fraction and volume of normal
brain irradiated.Table 3 Percentage Change between ibIMRT and sIMRT Plans for ea
Endpoint Median% diff
Mean Brain Dose Change 9.3%
Mean V40 Change 19.0%
Mean V20 Change 10.8%
Mean Contralateral Hippocampal Dose Change 13.5%
Mean PTVsr dose reduction in ibIMRT Plan 5.9%Although the relationship of dose tolerance and patho-
physiology of cortical brain tissue radiation effect is poorly
defined in adults, the dose level of 40Gy delivered over
6 weeks is significant as a moderate dose to normal brain
that may give rise to either impaired neuronal differenti-
ation or cerebrovascular impairment [13]. In patients
managed with RT in the 1990s for low grade glioma there
was an association with higher dose per fraction and
treated volume for late neurocognitive deficits [9]. More
recently volumetric analysis of cerebral cortex following
fractionated partial brain RT showed a dose dependent at-
rophy of cortex with doses beyond 35Gy [14]. RT tech-
niques have improved in recent years with superior target
delineation based on digital technology and MRI imaging
that may impact on historical volume of brain tissue
irradiated [15]. However the dose delivered in anaplastic
glioma can less be modified given presumed dose re-
sponse models for high-grade glioma, unless there a
risk-adapted approach can be implemented as per this
current study. Reduction of dose at this level by utilizing
integrated boost planning, without impacting negatively
on dose to tumour or low dose to normal brain, can thus
provide the potential for less morbidity.
For patients diagnosed with IDH mutated anaplastic
glioma the potential for survival extending beyond 10–15
years is high based on the long term outcome of the
RTOG9402 and EORTC26951trials published in 2013
[1, 2]. Despite these two studies being commenced in
the late 1990s before the improvements in digital imaging
and radiation dosimetry the use of adjuvant RT and
chemotherapy resulted in median survivals of 14.7 years
and beyond 11.7 years respectively for patients with
codeleted tumours. Future protocols need to consider
techniques that minimise late morbidity, as there is
now a population of patients who will be alive to ex-
perience the late impact of large volume radiation.ch patient






Fig. 1 Mean Brain Dose (cGy): Comparison of ibIMRT and sIMRT Plans for each patient
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history is the extensive nature of disease at initial presen-
tation with non-enhancing tumour extending beyond the
region that has transformed to high grade disease or more
densely clustered cells. Tumour extend across the corpus
callosum is not infrequent and may not only give rise to
neurocognitive deficits at presentation but also because to
the large volumes needed for irradiation place a higher
risk of late treatment morbidity. It is estimated that the
majority of patients with primary brain tumour will have
deficits on neuropsychological testing, the aetiology not
limited to neuronal damage from tumour or treatment
but also other factors such as seizure activity, anticonvul-
sants and neuro endocrine effects [7, 8, 16, 17].
The current protocol delivered a dose of 54Gy for the
low risk region as defined by absence of Gadolinium or
FDG uptake. The radiation dose response for anaplastic
glioma is poorly defined with doses historically correl-
ating with glioblastoma multiforme. However for low
grade glioma studies reviewing dose response have
shown no advantage for 64Gy versus 50.4 Gy [18] orFig. 2 V40 Brain Levels (%): Comparison of ibIMRT and sIMRT Plans for each45 Gy versus 54Gy [19]. Thus the use of 54Gy in the
area of glioma that has imaging features consistent with
low grade tumour can be justified.
MRI imaging remains the foundation for RT Planning
of brain tumours, though there are limitations in MRI
diagnosis as it is only partially able to determine the
metabolic activity of tumours. Generally blood brain bar-
rier (BBB) disruption and subsequent contrast enhance-
ment on MRI T1 sequences indicates the extent of high-
grade tumour. However in the scenario of non-enhancing
tumour where the BBB remains intact the extent of dis-
ease may be difficult to clarify [20].
Improving the therapeutic ratio of tumour control to
normal tissue morbidity through approaches such as this
integrated boost protocol is dependent upon accurate tar-
get volume delineation. Differentiating the T2 Flair change
from perilesional edema or non-enhancing tumour is one
of the difficult aspects of radiation treatment design for
patients with IDH mutated anaplastic gliomas; and the
proposed role of the FET PET is to determine the nature
of the T2 Flair component. It is believed that FET uptakepatient
Fig. 3 Percentage Change of normal brain endpoints between ibIMRT and sIMRT Plans for each patient
Back et al. Radiation Oncology  (2017) 12:46 Page 7 of 8will reflect that this is likely to be predominantly tumour
and less likely to be edema alone. Thus in the described
protocol the T2Flair is then treated to 54Gy. For radiation
oncologists whose protocols do not routinely include peri-
lesional edema, or those who dose reduce to 46Gy the
perilesional edema, then it is clinically important to be
able to define this MRI change.
In the protocol, the higher dose region for the integrated
boost was designed to optimize radiation dose to the areas
of higher biological activity. Whilst amino-acid tracers
have specificity in determining geographical extent of
tumour in normal brain, the scan may be less reliable in
indicating a region of higher metabolic activity or tumour
grade. In the absence of established data or more effica-
cious tracers, the higher glucose metabolism in FDG PET
was used to determine regions of higher grade (in addition
to any MRI gadolinium enhancement) for the integrated
boost. This is similar to the role of FDG PET to determine
increased tumour grade in patients being managed fol-
lowing radiological diagnosis of a low grade glioma.
Future opportunities exist in exploring novel PET
tracers that may isolate further regions in the tumour
that are of high risk and be targeted for dose painting
even beyond the standard 59.4Gy level. These may be
hypoxia tracers or improved amino acid tracers to
identify areas of higher proliferation [21]. Also with
the majority of these favourable glioma expressing an
IDH1 mutation, tracers targeting this protein may pro-
vide more specific determination of target volume to
potentially reduce extent of CTV.
Conclusions
An approach using ib-IMRT for anaplastic glioma pro-
duces significant dosimetric advantages in relation to nor-
mal brain dose compared with s-IMRT. This is achieved
without a significant reduction to the target volume dose
despite the reduction in prescribed dose. This technique
has advantages to minimise potential late neurocognitiveeffects from high dose radiation in patients with favorable
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